Review: 'Through the Shadowlands’ describes Julie Rehmeyer's ME/CFS Odyssey
I should note at the outset that this review is based on an audio version of the galleys and the epilogue from the finished work. Julie Rehmeyer sent me the final version as a PDF, but for some reason my text to voice software (Kurzweil) had issues with it. I understand that it is...
Discuss the article on the Forums.

Exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV

Discussion in 'Other Health News and Research' started by Kati, Jun 21, 2015.

  1. Kati

    Kati Patient in training

    Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation (open Access)


    The restoration of the immune system prompted by antiretroviral therapy (ART) has allowed drastically reducing the mortality and morbidity of HIV infection.

    However, one main source of clinical concern is the persistence of immune hyperactivation in individuals under ART. Chronically enhanced levels of T-cell activation are associated with several deleterious effects which lead to faster disease progression and slower CD4 + T-cell recovery during ART.

    In this article, we discuss the rationale, and review the results, of the use of antimalarial quinolines, such as chloroquine and its derivative hydroxychloroquine, to counteract immune activation in HIV infection.

    Despite the promising results of several pilot trials, the most recent clinical data indicate that antimalarial quinolines are unlikely to exert a marked beneficial effect on immune activation.

    Alternative approaches will likely be required to reproducibly decrease immune activation in the setting of HIV infection.

    If the quinoline-based strategies should nevertheless be pursued in future studies, particular care must be devoted to the dosage selection, in order to maximize the chances to obtain effective in vivo drug concentrations.
    beaker likes this.

See more popular forum discussions.

Share This Page